| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Neuphoria Therapeutics Inc. (NEUP) has 6 insiders with recent SEC Form 4 filings, including 1 buy and 0 sells. NEUP is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 875.3K | $3.77M | - | |
| CEO | 74.1K | $319.3K | - | |
| Dir | 30.7K | $132.5K | - | |
| Dir | 15.6K | $67.0K | - | |
| Dir | 15.4K | $66.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 21, 2025 | Lynx1 Capital Management LP45 | 10% Owner | Buy | 639,110 | $5.14 | $3,283,108.07 | +270.6% | -16.9% | - |